“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence
BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease
Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor
A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura
A Phase 1b dose escalation study with a Phase 2a expansion component to evaluate the safety and tolerability of ETC 1907206 in combination with dasatinib in advance hematologic malignancies